May your metabolic health stay optimized, your weight management stay sustainable, and your supplement choices stay evidence-based.
Precision is also paramount in terms of getting optimal treatment for people, and the appeal of different treatments might differ amongst people. GLP-1 Treatments Face Hurdles While GLP-1s offer promising benefits for some patients, significant barriers remain regarding supply, cost, and insurance coveragechallenges that Saunders describes as humongous limitations. Novo Nordisks Ozempic and Wegovy have been on the FDAs drug shortage list since 2022
Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, Thorens B
Mounjaro and Ozempic are primarily diabetes medications that also produce significant weight loss
The short answer is this: Foundayo and Rybelsus are not competitors